KALA BIO, Inc. (NasdaqCM: KALA)
Health Care · Biotechnology · US
$0.19
-35.40% today · -99.6% 1Y
KALA BIO, Inc. (NasdaqCM: KALA) operates in the Biotechnology industry within the Health Care sector. The company is valued at $3.67M and employs 6 people.
Over the last twelve months the share price has lost 99.6%, trading between 0.11 and 95.50.
Tweenvest scores KALA BIO, Inc. across four factors: quality 36/100, value 15/100. Its strongest factor is quality.
KALA price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $3.67M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -1.30
- Dividend yield
- —
- Beta (5Y)
- -2.41
- 52-week high
- $95.50
- 52-week low
- $0.11
- Avg volume (3M)
- —
- Shares outstanding
- 19.34M
- Employees
- 6
- Next earnings
- —
About KALA BIO, Inc.
Kala Bio, Inc. functions as a biopharmaceutical company dedicated to the creation and commercialization of new therapeutic solutions. The core of their strategy involves utilizing proprietary nanoparticle technology, specifically mucus penetrating particles (MPPs). Initially, their focus for these treatments is directed towards ophthalmic diseases. The company was established in 2009 by co-founders Justin Hanes, Robert S. Langer, and Colin R. Gardner, and its headquarters are located in Arlington, Massachusetts.
- ISIN
- US4831193010
- Founded
- 2009
- Listed since
- Jul 20, 2017
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Liminatus Pharma, Inc.NasdaqCM: LIMN | $4.08M | $3.04 | -19.15% |
| Enlivex Ltd.NasdaqCM: ENLV | $4.08M | $0.21 | -19.29% |
| Biotron LimitedASX: BIT | $3.88M | AU$0.00 | -20.00% |
| Genetic Analysis ASXSAT: GEAN | $3.82M | Nkr— | — |
| PharmaCyte Biotech, Inc.NasdaqCM: PMCB | $3.65M | $0.34 | -15.88% |
| StageZero Life Sciences Ltd.TSXV: SZLS.H | $3.64M | CA$— | — |
| Tissue Repair LtdASX: TRP | $3.56M | AU$0.09 | -5.56% |
| Dermata Therapeutics, Inc.NasdaqCM: DRMA | $3.46M | $0.86 | -15.69% |
Figures last refreshed Oct 18, 2026.